Reports Q2 revenue $232.1M, consensus $211.3M. “Q2 was another exceptional quarter for Guardant and we were able to increase our 2025 revenue guidance yet again. We saw especially strong performance from Guardant360 Liquid, where year-over-year growth accelerated for the fourth consecutive quarter,” said Helmy Eltoukhy, co-founder and co-CEO. “In May, we introduced 11 groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid, significantly expanding the clinical utility. Product innovation built on Smart Liquid Biopsy is integral to our strategy at Guardant and we look forward to continuing a steady cadence of SLB-based applications to further extend our technical leadership in the comprehensive genomic profiling market. “
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health announces RADIOHEAD study validates Guardant Reveal use
- ILMN, NVDA: Cathie Wood Pours Over 5 Million Into Biotech and AI Stocks, Cuts RKLB Stake Again
- Guardant Health announces patient enrollment in Vanguard Study
- Supreme Court keeps element of Obamacare preventive care, Reuters reports
- Guardant Health Elects Board and Approves Auditor